IMMUNOLOGICAL STUDY OF HUMAN RECOMBINANT INTERLEUKIN-2 (LOW-DOSE) IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA

被引：25
|
作者：
MARUMO, K [1 ]
MURAKI, J [1 ]
UENO, M [1 ]
TACHIBANA, M [1 ]
DEGUCHI, N [1 ]
BABA, S [1 ]
JITSUKAWA, S [1 ]
HATA, M [1 ]
TAZAKI, H [1 ]
机构：
[1] KEIO UNIV,SCH MED,DEPT UROL,TOKYO 108,JAPAN
来源：
UROLOGY | 1989年 / 33卷 / 03期
关键词：
D O I：
10.1016/0090-4295(89)90396-8
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：219 / 225
页数：7
相关论文
共 50 条
  • [31] RENAL-CELL CARCINOMA AND INTERLEUKIN-2 - A REVIEW
    WAGSTAFF, J
    BAARS, JW
    WOLBINK, GJ
    HOEKMAN, K
    EERENBERGBELMER, AJM
    HACK, CE
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (03) : 401 - 408
  • [32] Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application
    Kirchner, GI
    Franzke, A
    Buer, J
    Beil, W
    Probst-Kepper, M
    Wittke, F
    Övermann, K
    Lassmann, S
    Hoffmann, R
    Kirchner, H
    Ganser, A
    Atzpodien, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (01) : 5 - 10
  • [33] Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma
    Buzio, C
    Andrulli, S
    Santi, R
    Pavone, L
    Passalacqua, R
    Potenzoni, D
    Ferrozzi, F
    Giacosa, R
    Vaglio, A
    CANCER, 2001, 92 (09) : 2286 - 2296
  • [34] A RANDOMIZED STUDY OF LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS IMMUNOTHERAPY VERSUS INTERLEUKIN-2 PLUS INTERFERON-ALPHA AS FIRST LINE THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
    LISSONI, P
    BARNI, S
    ARDIZZOIA, A
    ANDRES, M
    SCARDINO, E
    CARDELLINI, P
    DELLABITTA, R
    TANCINI, G
    TUMORI, 1993, 79 (06) : 397 - 400
  • [35] Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma
    Freedman, RS
    Gibbons, JA
    Giedlin, M
    Kudelka, AP
    Kavanagh, JJ
    Edwards, CL
    Carrasco, CH
    Nash, MA
    Platsoucas, CD
    JOURNAL OF IMMUNOTHERAPY, 1996, 19 (06): : 443 - 451
  • [36] A COMBINATION OF SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA IN THE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA OR MELANOMA
    VUORISTO, M
    JANTUNEN, I
    PYRHONEN, S
    MUHONEN, T
    KELLOKUMPULEHTINEN, P
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (04) : 530 - 532
  • [37] LOW-DOSE REGIMEN OF INTERLEUKIN-2 FOR METASTATIC RENAL-CARCINOMA
    SLEIJFER, DT
    JANSSEN, RAJ
    WILLEMSE, PHB
    MARTENS, A
    DELEIJ, L
    DEVRIES, EGE
    MULDER, NH
    LANCET, 1990, 335 (8704): : 1522 - 1523
  • [38] LABORATORY CORRELATES OF CHEMOIMMUNOTHERAPY WITH LOW-DOSE RECOMBINANT INTERLEUKIN-2 AND MITOMYCIN-C IN PATIENTS WITH ADVANCED-CARCINOMA
    ARINAGA, S
    KARIMINE, N
    TAKAMUKU, K
    NANBARA, S
    INOUE, H
    ABE, R
    WATANABE, D
    ASOH, T
    UEO, H
    AKIYOSHI, T
    CANCER INVESTIGATION, 1994, 12 (06) : 588 - 596
  • [39] LOW-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY IN ADVANCED MULTIPLE-MYELOMA
    PEEST, D
    LEO, R
    BLOCHE, S
    HEIN, R
    STANNATKIESSLING, S
    TSCHECHNE, B
    FETT, W
    HARMS, P
    HOFFMANN, L
    BARTL, R
    WACKER, HH
    GORG, S
    ATZPODIEN, J
    KIRCHNER, H
    DEICHER, H
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (02) : 328 - 337
  • [40] HIGH-DOSE INTERLEUKIN-2 IN THE THERAPY OF METASTATIC RENAL-CELL CARCINOMA
    PARKINSON, DR
    SZNOL, M
    SEMINARS IN ONCOLOGY, 1995, 22 (01) : 61 - 66
12345